Synopsis:

Keith Gottesdiener, MD, and Jeremy Duffield, MD, PhD, FRCP, are the President & CEO and CSO, respectively, of Prime Medicine. Prime Medicine was founded to bring the promise of gene editing to patients. They use Prime Editing, a next-generation technology that can “search and replace” to restore normal genetic function almost anywhere in the genome. Keith and Jeremy discuss the arc of their careers and how they go to where they are today. They talk about the differences working in big pharma vs. a smaller biotech like Prime. They discuss the importance of companies investing in safety and what they’ve learned in terms of indication selection frameworks within the context of gene editing. Finally, they talk about their goal of engaging in partnerships down the road, and the importance of having transparency within their organization.

Biography:

Keith Gottesdiener, MD is President and Chief Executive Officer of Prime Medicine and has served as a member of our Board of Directors since July 2020. From October 2011 until March 2020, Dr. Gottesdiener served as the Chief Executive Officer and a director of Rhythm Pharmaceuticals, Inc., a biopharmaceutical company that develops therapeutics in rare genetic obesity. During that time, Rhythm submitted a New Drug Application for setmelanotide in two indications, for which setmelanotide was subsequently approved.

Dr. Gottesdiener received his B.A. from Harvard College and his M.D. from the University of Pennsylvania. He completed his residency and fellowship at the Brigham and Women’s Hospital-Beth Israel Medical Center-Dana Farber Cancer Institute Children’s Hospital programs. After his fellowship, Dr. Gottesdiener did postdoctoral research in the laboratory of Dr. Jack Strominger at the Dana Farber Cancer Institute. He then joined the faculty as an assistant professor at Columbia University, where he started an independent research laboratory with NIH RO-1 funding, ending his academic career as Associate Clinical Professor of Medicine at the time he left to join Merck in 1995.

Jeremy Duffield, MD, PhD, FRCP, is the Chief Scientific Officer of Prime Medicine. He has many years of drug discovery experience at Vertex Pharmaceuticals and Biogen Inc. preceded by a distinguished career in academic medicine.

Dr. Duffield has held several leadership roles, with focus in the fields of human genetics, innate immunity and regenerative medicine. He served as Global Head of Human Biology at Vertex Pharmaceuticals and as Vice President of Business Development where he and his team played important roles in discovering and advancing candidates to clinical studies in rare diseases including cystic fibrosis, a1-antitrypsin deficiency, sickle cell disease, FSGS and muscular dystrophies. Several candidates are now approved therapies. He was instrumental in building Vertex Cell and Genetic Therapies.

At Biogen, Dr. Duffield served as Senior Research Fellow and Vice President with responsibilities in early research programs, as joint Head of Innate Immunity and Regenerative Medicine therapeutic area, and as Head of the Biogen Post-Doctoral program. There he contributed to advancing integrin inhibitors, TNF superfamily inhibitors and IRAK inhibitors to clinical evaluation for pulmonary fibrosis and autoimmune diseases.

Dr. Duffield received his B.A. and M.D. (B.M., B.Ch.) from Oxford University and a Ph.D. in Immunology from the University of Edinburgh in the laboratory of Sir John Savill.